Is XDR-TB a sub-group of MDR-TB? Need to reorganize alphabets again

Indian Journal of Tuberculosis

Volumn 59, Issue 4, 2012, Pages 187-189

  Karkhanis, Vinaya S ^a   Joshi, Jyotsna M ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; REPRODUCIBILITY; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872164616     PISSN: 00195707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Guidelines for the programmatic management of drug-resistant tuberculosis (May 2012) World Health Organization, Geneva.
2. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154-60.
3. Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta U, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011; 134: 281-94
4. Holloway K, Mathai E, Gray A. Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings Project Group. Surveillance of community antimicrobial use in resource-constrained settings-experience from five pilot projects. Trop Med Int Health 2011; 16: 152-61
5. Devasia RA, Blackman A, May C, Eden S, Smith T, Hooper N, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63: 1173-8.
6. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment Outcomes and Survival Based on Drug Resistance Patterns in Multidrug-resistant Tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-9.
7. Kim S J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-9.
8. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, Zignol M, et al. Determination of critical concentrations of secondline anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-8.
9. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line anti tuberculosis drugs. WHO/HTM/TB/2008.
10. World Health Organization. Extensively drug-resistant tuberculosis (XDR.TB): recommendations for prevention and control. Weekly Epidemiol Record 2006; 81: 430-2.
11. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-81.
12. Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012.doi:10.1016/S0140-6736(12)60734-X.
13. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modeling study. Lancet 2007; 370: 1500-07.
14. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-7.